HC Wainwright Has Bearish Estimate for CAPR FY2026 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Capricor Therapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($2.76) per share for the year, down from their previous estimate of ($2.75). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.71) per share.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29).

A number of other research firms also recently issued reports on CAPR. Cantor Fitzgerald upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Ladenburg Thalmann & Co. Inc. cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $5.00 to $21.00 in a research report on Monday, September 14th. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a research report on Tuesday, July 28th. Finally, JonesTrading upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $29.77.

Capricor Therapeutics Stock Down 8.7%

Shares of CAPR stock opened at $10.24 on Friday. The business’s fifty day moving average is $8.10 and its 200 day moving average is $19.92. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Montanova Capital LLC grew its stake in shares of Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after buying an additional 274,184 shares during the last quarter. Bank of America Corp DE increased its position in Capricor Therapeutics by 672.0% during the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after buying an additional 361,664 shares in the last quarter. Walleye Capital LLC bought a new position in Capricor Therapeutics during the 1st quarter valued at approximately $5,397,000. Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 10.4% during the 1st quarter. Bank of New York Mellon Corp now owns 130,730 shares of the biotechnology company’s stock valued at $3,974,000 after buying an additional 12,366 shares in the last quarter. Finally, Ally Bridge Group NY LLC purchased a new position in Capricor Therapeutics during the first quarter valued at $3,463,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.